EPAS1 and renal cell carcinoma: Belzutifan was associated with predominantly grade 1 and 2 adverse events and showed HIF-2α inhibitory activity in patients with renal cell carcinomas and non-renal cell carcinoma neoplasms associated with VHL disease [14].